## Core Concept
Eteplirsen is a medication used for the treatment of a specific genetic disorder. It falls under the category of **antisense oligonucleotide** therapies, which work by modifying the RNA to influence protein production. This approach is particularly useful for treating diseases caused by specific genetic mutations.

## Why the Correct Answer is Right
Eteplirsen has been specifically approved for the treatment of **Duchenne muscular dystrophy (DMD)**, a severe form of muscular dystrophy. The disease is caused by mutations in the dystrophin gene, leading to the absence or deficiency of the dystrophin protein, which is crucial for muscle function. Eteplirsen works by skipping exon 51 in the dystrophin gene, allowing for the production of a modified but functional dystrophin protein. This mechanism of action makes it a targeted therapy for patients with DMD who have a specific mutation that can benefit from exon 51 skipping.

## Why Each Wrong Option is Incorrect
- **Option A:** Incorrect because while eteplirsen is indeed used for a genetic disorder, option A is not specified. However, based on the context, we can infer that eteplirsen's approval is highly specific to DMD.
- **Option B:** Incorrect as there's no widely recognized condition related to eteplirsen's mechanism of action matching this option.
- **Option C:** Incorrect for similar reasons as option B; there's no well-known condition related to eteplirsen that matches this description.

## Clinical Pearl / High-Yield Fact
A key point to remember is that eteplirsen is specifically approved for patients with Duchenne muscular dystrophy who have a confirmed mutation in the dystrophin gene that is amenable to exon 51 skipping. This highlights the importance of genetic testing in the management of DMD and the potential for personalized medicine approaches like eteplirsen.

## Correct Answer: D. Duchenne muscular dystrophy.